This binding results in activation of estrogenic pathways in some tissues (agonism) and and the blockade of estrogenic pathways in other
tissues (antagonism). The agonistic or antagonistic activity of
raloxiffene depends on the extent of recruitment of coactivators and
corepressors to estrogen receptor (ER) target gene promotors.
Raloxifene Hcl appears to act as an estrogen agonist in bone. It decreases bone resorption and bone turnover, increases bone mineral
density and decreases fracture incidence.
Raloxifene Hydrochloride Application:
1) Raloxifene Hcl used to prevent & treat osteoporosis in women who have undergone menopause.
2) Raloxifene Hcl used to decrease the risk of developing invasive breast cancer in women who are at high risk of developing this type of
cancer or who have osteoporosis. Raloxifene Hcl cannot be used to treat
invasive breast cancer or to prevent invasive breast cancer from coming
back in women who have already had the condition.
3) Raloxifene Hcl prevents and treats osteoporosis by mimicking the effects of estrogen to increase the density (thickness) of bone.
4) Raloxifene Hcl decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue, which may
stop the development of tumors that need estrogen to grow.